The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction.
As privileged witnesses of the initiation and widespread use of reperfusion therapy the authors review the history of fibrinolytic therapy and of tissue-plasminogen activator (t-PA) more particularly and the current indications for its use in the era of mechanical reperfusion.
Van de Werf
F J
FJ
Department of Cardiology, University Hospitals Leuven, Leuven, Belgium. frans.vandewerf@uz.kuleuven.ac.be
Topol
E J
EJ
Sobel
B E
BE
D000925:Anticoagulants / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000266:history / Q000639:trends; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator